HR Execs on the Move

Praxsyn

www.praxsyn.com

 
Headquartered in Irvine, California, Praxsyn works to realize the vision of medical professionals to improve the lives of patients. Mesa Pharmacy, a wholly owned subsidiary, provides doctors with an alternative to oral pain medications. Mesa focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and medical clinics. Mesa has developed a series of topical creams, in different strengths, that provide the pain relief doctors seek for their patients.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.praxsyn.com
  • 1803 Sky Park Circle Suite A
    Irvine, CA USA 92614
  • Phone: 949.777.6112

Executives

Name Title Contact Details

Similar Companies

Path-Tec

Path-Tec is a leading provider of specimen collection kits and components. Our specialty is detailed specimen management. We understand the importance of specimen integrity so we work with laboratories to design kits that assist with proper specimen co...

Medical Components

Dialysis and Vascular Access Products

Cary Pharmaceuticals Inc

Cary Pharmaceuticals Inc is a Great Falls, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RPM Systems

RPM Systems is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elevar Therapeutics

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar`s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (paclitaxel micellar). Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014). It has been granted Orphan Drug designation in the U.S., Europe and South Korea and has been clinically tested in over 1,000 patients worldwide in numerous cancer indications. Apealea® (paclitaxel micellar) is a non-Cremophor EL based formulation of paclitaxel that received marketing authorization by the European Commission in November 2018, making it Europe`s first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has offices in Utah, California and South Korea.